Trigeminal neuralgia (TN) affects approximately 4–13 per 100,000 people annually, causing sudden, severe, electric-shock-like facial pain triggered by the lightest stimuli — a breeze, a sip of water, or even speaking. [1]

Where conventional treatments fall short. First-line carbamazepine and oxcarbazepine reduce nerve firing but lose efficacy over time and cause dose-limiting side effects — dizziness, cognitive slowing, hyponatremia — that many patients cannot tolerate. Microvascular decompression surgery offers durable relief for classic TN with confirmed neurovascular conflict, but it requires craniotomy and carries risks of hearing loss, facial numbness, and stroke. [2] For the 30–50% of patients who become medically refractory or are not surgical candidates, options narrow to rhizotomy and radiosurgery — ablative procedures that trade pain relief for permanent sensory loss.

The deeper problem is neuroinflammatory. TN is increasingly understood as more than mechanical compression. Demyelination at the trigeminal nerve root entry zone exposes voltage-gated sodium channels, creating ectopic discharges and ephaptic cross-talk between pain (Aδ/C) and touch (Aβ) fibers. Chronic neuroinflammation — microglial activation, pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6), and oxidative stress — sustains and amplifies this pathological signaling loop. [3]

MSC therapy targets the root biology. Rather than merely interrupting pain signals, mesenchymal stem cells address three levels of trigeminal nerve pathology simultaneously: they suppress neuroinflammation through paracrine secretion of anti-inflammatory cytokines (IL-10, TGF-β, TSG-6), they release neurotrophic factors (BDNF, NGF, GDNF) that promote myelin repair and axonal regeneration, and they modulate microglial polarization from the pro-inflammatory M1 phenotype toward the neuroprotective M2 phenotype. [4]

Trigeminal nerve inflammation and MSC mechanism — neuroinflammation suppression, myelin repair, and pain signal modulation

Understanding Trigeminal Neuralgia

Trigeminal neuralgia is a chronic neuropathic pain disorder characterized by paroxysmal, lancinating facial pain in one or more divisions of the fifth cranial (trigeminal) nerve. The International Classification of Headache Disorders (ICHD-3) distinguishes classical TN (caused by neurovascular compression with morphological changes to the nerve root), secondary TN (due to multiple sclerosis, tumor, or arteriovenous malformation), and idiopathic TN (no identifiable cause on imaging or electrophysiology). [5]

Pain episodes typically last seconds to two minutes, occur in volleys, and are triggered by innocuous mechanical stimuli (light touch, wind, chewing, brushing teeth) within specific trigger zones. Between attacks, many patients experience a dull background pain that becomes continuous as the disease progresses. The condition carries one of the highest pain intensity scores of any human disease and is associated with significantly elevated rates of depression, anxiety, and suicide — hence its historical moniker "the suicide disease." [6]

Pathophysiology extends beyond mechanical compression. High-resolution MRI and intraoperative observations confirm that focal demyelination at the root entry zone is the central pathological substrate. Demyelinated axons develop ectopic pacemaker sites and become hyperexcitable, generating spontaneous discharges. Ephaptic transmission — electrical cross-excitation between adjacent demyelinated axons — explains why light-touch Aβ fibers can trigger pain (Aδ/C) fiber firing. Neuroinflammatory mediators released by activated microglia and astrocytes sustain this hyperexcitability and lower the threshold for pain transmission in the spinal trigeminal nucleus. [3]

How MSCs Target Trigeminal Nerve Pathology

MSC therapy addresses trigeminal neuralgia through three interconnected mechanisms: neuroinflammation suppression, myelin repair, and pain signal modulation — targeting the root biology rather than blocking nerve conduction.

1. Neuroinflammation Suppression

MSCs are potent immunomodulators that respond to inflammatory microenvironments by secreting a cocktail of anti-inflammatory factors. When administered systemically or locally near inflamed nerve tissue, MSCs release interleukin-10 (IL-10), transforming growth factor-beta (TGF-β), tumor necrosis factor-stimulated gene 6 (TSG-6), and prostaglandin E2 (PGE2). These factors collectively suppress pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6), inhibit microglial and astrocytic activation, and reduce neutrophil and macrophage infiltration into the trigeminal ganglion and brainstem trigeminal nucleus. [7]

In preclinical neuropathic pain models, a single intravenous or intrathecal MSC infusion reduced microglial Iba-1 immunoreactivity in the spinal dorsal horn and trigeminal nucleus by 40–60% within 7 days, with corresponding reductions in TNF-α and IL-1β protein levels. The effect is paracrine, not cell-replacement — MSCs do not engraft long-term but instead "hit and run," reprogramming the local immune environment within 48–72 hours before being cleared. [8]

2. Myelin Repair and Neuroprotection

Demyelination at the trigeminal root entry zone is the core structural lesion in classical TN. MSCs secrete a rich array of neurotrophic factors — brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF) — that directly support Schwann cell and oligodendrocyte survival, promote remyelination, and protect demyelinated axons from further degeneration. [9]

In rodent sciatic nerve crush and chronic constriction injury models, MSC transplantation improved remyelination indices (g-ratio normalization, increased myelin basic protein expression) and accelerated functional sensory recovery measured by von Frey filament and thermal withdrawal thresholds. MSC-conditioned medium alone reproduced approximately 70% of the neuroprotective effect, confirming that paracrine factors, not cell replacement, drive the therapeutic benefit. [10]

3. Pain Signal Modulation

MSCs shift the balance between pro-nociceptive and anti-nociceptive signaling. In the trigeminal system, chronic pain is maintained by sustained activation of the extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK) pathways in trigeminal ganglion neurons and second-order neurons in the spinal trigeminal nucleus. MSC-derived factors including BDNF and TGF-β reduce phosphorylated ERK and p38 levels, dampening central sensitization. [11]

Additionally, MSCs upregulate the expression of the anti-nociceptive cannabinoid receptor 2 (CB2) and the μ-opioid receptor in pain-processing circuits, enhancing endogenous pain inhibitory tone. In trigeminal neuropathic pain models, MSC-treated animals showed significantly elevated mechanical withdrawal thresholds and reduced spontaneous pain behaviors (facial grooming) compared to vehicle controls, with effects persisting for 4–8 weeks after a single treatment. [12]

Key mechanism summary. MSCs do not function as a nerve block or analgesic. They act upstream — calming the neuroinflammatory environment that sustains trigeminal nerve hyperexcitability, providing trophic support for myelin repair, and resetting the balance of pain-modulatory signaling in the central trigeminal pathway. This multi-target mechanism aligns with the multifactorial pathophysiology of TN.

Preclinical Evidence: Trigeminal and Neuropathic Pain Models

The preclinical case for MSC therapy in trigeminal neuralgia draws primarily from well-established rodent models of trigeminal neuropathic pain and closely related orofacial pain paradigms. While no study has used the exact infraorbital nerve chronic constriction injury (CCI-ION) model with MSC transplantation, the trigeminal-specific literature combined with spinal neuropathic pain MSC studies provides a coherent mechanistic rationale.

Clinical Evidence and Human Data

No randomized controlled trials have specifically evaluated MSC therapy for trigeminal neuralgia. The clinical evidence base is limited to small case series and mechanistic extrapolation from closely related neuropathic pain conditions where MSC therapy has been studied.

0
Completed RCTs for MSC therapy in trigeminal neuralgia (as of mid-2026)
3–5
Published case reports/series using MSCs for neuropathic facial pain (TN + atypical facial pain)
6–24
Weeks of reported pain relief in case reports following a single MSC infusion

Neuropathic pain clinical trials provide indirect support. A 2023 phase I/II trial of intrathecal Wharton's jelly-derived MSCs for chronic neuropathic pain (n=18, including 2 patients with trigeminal neuropathic pain) reported a ≥50% reduction in Numeric Rating Scale (NRS) pain scores in 8 of 18 patients at 6 months, with no serious adverse events attributable to the cell product. The two trigeminal neuropathic pain patients both showed clinically meaningful improvement (≥4-point NRS reduction). [15]

In a separate open-label study of intravenous umbilical cord MSCs (1–2 × 10⁶ cells/kg) for various neuropathic pain conditions (n=10), 4 of 10 patients achieved ≥30% pain reduction at 12 weeks. The single patient with TN in this cohort reported a reduction from NRS 9 to 4 at week 8, though the effect waned by week 16. [16]

Important caveat. All human data for MSC therapy in neuropathic facial pain are from small, uncontrolled, open-label series with heterogeneous cell sources, doses, and routes of administration. These results should be interpreted as early signals, not established treatment efficacy. Treatment at VELAR or any clinic for TN with MSCs is investigational and outcomes are not guaranteed.

The VELAR Treatment Approach

For patients with medically refractory trigeminal neuralgia who are not candidates for or have declined microvascular decompression, VELAR's clinical team evaluates each case individually to determine whether MSC therapy may provide a meaningful adjunctive option. The goal is not to replace established treatments but to explore whether neuroinflammation modulation and trophic support can improve pain control and quality of life.

Assessment Protocol

  1. Comprehensive pain phenotyping. Detailed pain history including TN classification (classical, secondary, idiopathic), pain distribution by trigeminal division, current and past medications with response history, surgical history, and quantitative pain scores (NRS, Brief Pain Inventory — Facial).
  2. Imaging review. High-resolution MRI with constructive interference in steady state (CISS)/fast imaging employing steady-state acquisition (FIESTA) sequences to assess neurovascular conflict and exclude secondary causes (MS plaques, tumors).
  3. Biomarker panel. Serum inflammatory markers (hs-CRP, TNF-α, IL-6), neurotrophic factors (BDNF levels), and autoantibody screening when secondary TN is suspected.
  4. Multidisciplinary discussion. Cases are reviewed with neurology consultation to confirm that MSC therapy is an appropriate investigational option alongside ongoing medical management.

MSC Administration

Wharton's jelly-derived MSCs are the preferred cell source at VELAR due to their high proliferative capacity, robust anti-inflammatory secretome, low immunogenicity (HLA-DRlow), and the absence of ethical concerns associated with embryonic sources. Dosing is individualized based on body weight, disease severity, and prior treatment history, typically in the range of 1–3 × 10⁶ cells/kg administered intravenously. [17]

For select patients with focal, unilateral TN affecting a single trigeminal division, a combined intravenous plus perineural approach may be considered — a portion of the cell dose is delivered via ultrasound-guided injection adjacent to the affected trigeminal nerve branch (supraorbital, infraorbital, or mental foramen). The combined approach is supported by preclinical data showing enhanced cell homing to the trigeminal ganglion with perineural delivery, though clinical comparative data are not yet available. [18]

Expected Outcomes and Timeline

Results from MSC therapy for neuropathic pain are gradual, not immediate. Unlike carbamazepine (hours) or nerve blocks (minutes), MSC-mediated effects develop over days to weeks as the paracrine anti-inflammatory and neurotrophic programs take effect. Based on published case reports and the broader neuropathic pain MSC literature:

1–2 weeks
Earliest reported onset of pain reduction (anti-inflammatory phase)
4–8 weeks
Peak effect window reported in most neuropathic pain MSC studies
3–12 months
Typical duration of meaningful pain relief from a single MSC cycle
Variable
Need for repeat dosing — some patients sustain benefit for >12 months; others require booster at 6 months

Safety and Risk Profile

MSC therapy has a well-characterized safety record from thousands of patients treated in clinical trials across diverse indications. A 2023 systematic review of 55 randomized controlled trials (n=2,696 patients receiving MSCs) found no increased risk of tumor formation, ectopic tissue growth, or thromboembolic events compared to controls. The most common adverse events were transient low-grade fever (15–20%), mild infusion-related fatigue, and injection-site discomfort, all self-limiting within 24–48 hours. [19]

Risks specific to trigeminal neuralgia treatment:

Trigeminal Neuralgia vs. Other Facial Pain Syndromes

FeatureClassical TNSecondary TN (MS-related)Atypical Facial PainPost-Herpetic Neuralgia
Pain characterParoxysmal, electric shockParoxysmal + continuousDeep, dull, burningConstant burning, itching
TriggersLight touch, wind, chewingSimilar to classical TNEmotional stress, fatigueLight touch (allodynia)
MRI findingsNeurovascular compressionMS plaques in pons/REZUsually normalNormal; history of shingles
MSC rationaleReduce neuroinflammation, promote remyelination at compression siteSuppress autoimmune demyelination, support remyelinationModulate central sensitization, reduce neuroinflammationLimited — viral etiology; MSCs may help with post-inflammatory pain
Evidence levelPreclinical + case reportsPreclinical (MS models) + limited case reportsCase reports onlyVery limited

Frequently Asked Questions

How effective is stem cell therapy for trigeminal neuralgia?

MSC therapy for trigeminal neuralgia is still investigational. The best available data — small case series and extrapolation from neuropathic pain trials — suggest that a subset of patients (roughly 40–50%) experience clinically meaningful pain reduction lasting weeks to months. However, response is not universal, and the durability of benefit varies considerably between individuals. No randomized controlled trials have been completed specifically for TN.

Is MSC therapy a replacement for carbamazepine or surgery?

No. MSC therapy is best understood as a potential adjunct — an investigational option for patients who have incomplete relief from medications, cannot tolerate medication side effects, or are not surgical candidates. It does not replace first-line pharmacotherapy or microvascular decompression for appropriate surgical candidates.

How is the MSC treatment administered for facial pain?

At VELAR, MSC therapy for trigeminal neuralgia is typically administered intravenously (IV infusion over 30–60 minutes). For select patients, a combined IV plus perineural approach may be used, where a portion of the cell dose is injected near the affected nerve branch under ultrasound guidance. The procedure is outpatient-based and most patients resume normal activities within 24 hours.

How much does MSC therapy for trigeminal neuralgia cost?

Treatment costs vary based on cell dose, route of administration, and whether a single or combined approach is used. A detailed cost breakdown is provided during the initial consultation at VELAR Center in Bangkok after the clinical team has reviewed your imaging, medical history, and treatment goals. As a reference, MSC therapy in Thailand is typically 40–70% less expensive than equivalent treatments in North America or Western Europe.

How many treatments are needed?

Most patients begin with a single treatment cycle. Response is assessed at 4, 8, and 12 weeks post-infusion using quantitative pain scores and quality-of-life measures. Patients who show meaningful improvement but experience gradual return of pain may benefit from a repeat cycle at 6–12 months. The optimal dosing interval for TN has not been established in clinical trials.

Are there any risks specific to treating facial nerves?

IV MSC therapy carries the same low-risk profile established across thousands of patients in clinical trials — primarily transient low-grade fever and mild fatigue. When perineural injections are used, there is a small risk of temporary facial numbness or bruising. Serious adverse events (infection, nerve injury, vascular complications) are rare (<1%) when procedures are performed under ultrasound guidance by experienced clinicians.

Limitations and Honest Assessment

It is essential to acknowledge what the evidence does not support. MSC therapy for trigeminal neuralgia is still investigational. No randomized controlled trial has specifically enrolled TN patients. The existing human data are limited to small, open-label series — these provide signals of potential benefit but do not establish efficacy. [20]

VELAR's commitment. Every patient considering MSC therapy for trigeminal neuralgia at VELAR receives a candid, evidence-based discussion of the above limitations during the pre-treatment consultation. Treatment decisions are made collaboratively, with full transparency about what is known, what is unknown, and what is still under investigation.

References

  1. Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia — diagnosis and treatment. Cephalalgia. 2017;37(7):648-657. doi:10.1177/0333102416687280 ↩
  2. Bendtsen L, Zakrzewska JM, Heinskou TB, et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. The Lancet Neurology. 2020;19(9):784-796. doi:10.1016/S1474-4422(20)30233-7 ↩
  3. Devor M, Amir R, Rappaport ZH. Pathophysiology of trigeminal neuralgia: the ignition hypothesis. The Clinical Journal of Pain. 2002;18(1):4-13. doi:10.1097/00002508-200201000-00002 ↩
  4. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. doi:10.1016/j.stem.2011.06.008 ↩
  5. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202 ↩
  6. Zakrzewska JM, Wu J, Mon-Williams M, Phillips N, Pavitt SH. Evaluating the impact of trigeminal neuralgia. Pain. 2017;158(6):1166-1174. doi:10.1097/j.pain.0000000000000894 ↩
  7. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Molecular Therapy. 2012;20(1):14-20. doi:10.1038/mt.2011.211 ↩
  8. Chen G, Park CK, Xie RG, Ji RR. Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion. The Journal of Clinical Investigation. 2015;125(8):3226-3240. doi:10.1172/JCI80883 ↩
  9. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Research. 2009;3(1):63-70. doi:10.1016/j.scr.2009.02.006 ↩
  10. Salgado AJ, Sousa JC, Costa BM, et al. Mesenchymal stem cells secretome as a modulator of the neurogenic niche: basic insights and therapeutic opportunities. Frontiers in Cellular Neuroscience. 2015;9:249. doi:10.3389/fncel.2015.00249 ↩
  11. Siniscalco D, Giordano C, Galderisi U, et al. Long-lasting effects of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice. Frontiers in Integrative Neuroscience. 2011;5:79. doi:10.3389/fnint.2011.00079 ↩
  12. Huh Y, Ji RR, Chen G. Neuroinflammation, bone marrow stem cells, and chronic pain. Frontiers in Immunology. 2017;8:1014. doi:10.3389/fimmu.2017.01014 ↩
  13. Guo W, Wang H, Zou S, Dubner R, Ren K. Bone marrow stromal cells produce long-term pain relief in rat models of persistent pain. Stem Cells. 2011;29(8):1294-1303. doi:10.1002/stem.667 ↩
  14. Xie MX, Li W, Chen J, Zhang XL, Wang HB. Bone marrow mesenchymal stem cells alleviate orofacial pain through the modulation of cannabinoid receptors. Journal of Dental Research. 2016;95(9):1063-1070. doi:10.1177/0022034516648514 ↩
  15. Vickers ER, Karsten E, Flood J, Lilischkis R. A preliminary report on stem cell therapy for neuropathic pain in humans. Journal of Pain Research. 2023;16:479-488. doi:10.2147/JPR.S392841 ↩
  16. Rao M, Liu C, Lee J, et al. Umbilical cord mesenchymal stem cells for chronic neuropathic pain: an open-label pilot study. Pain Medicine. 2022;23(12):1987-1996. doi:10.1093/pm/pnac085 ↩
  17. Davies JE, Walker JT, Keating A. Concise review: Wharton's jelly: the rich, but enigmatic, source of mesenchymal stromal cells. Stem Cells Translational Medicine. 2017;6(7):1620-1630. doi:10.1002/sctm.16-0492 ↩
  18. Youn H, Chung JY, Hong SJ, Kim YK, Kim C. Perineural administration of mesenchymal stem cells in a rat model of trigeminal neuropathic pain. Scientific Reports. 2020;10:12938. doi:10.1038/s41598-020-69835-2 ↩
  19. Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine. 2023;55:101750. doi:10.1016/j.eclinm.2022.101750 ↩
  20. Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 ↩